Eisai, Daiichi Sankyo Vulnerable To Generic Competition As Patents Fall
This article was originally published in PharmAsia News
Executive Summary
Eisai and Daiichi Sankyo are expected to follow in the footsteps of Japan's two largest drug makers, Takeda Pharmaceutical and Astellas Pharma, in losing sales as patents expire